Small heterodimer partner as a predictor of neoadjuvant radiochemotherapy response and survival in patients with rectal cancer: A preliminary study

Small heterodimer partner (SHP) plays an essential role in the regulation of innate immune and inflammatory responses. The aim of the present study was to identify whether SHP levels are associated with cancer immunology and treatment outcomes in rectal cancer. SHP expression was analyzed via gene s...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2021-10, Vol.22 (4), p.1, Article 708
Main Authors: Kim, Sup, Joo, Mina, Yeo, Mln-Kyung, Cho, Moon-June, Kim, Jun-Sang, Jo, Eun-Kyeong, Kim, Jin-Man
Format: Article
Language:English
Subjects:
Bioinformatics
Biomarkers
Breast cancer
Cancer
Cancer patients
Cancer therapies
Care and treatment
Chemotherapy
Colorectal cancer
Estrogens
Gene expression
Genes
Genetic transcription
Immunohistochemistry
Inflammation
Lymphocytes
Medical prognosis
Metastasis
Oncology
Oncology, Experimental
Patient outcomes
Patients
Radiation therapy
RNA
Statistical analysis
Surgery
T cells
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small heterodimer partner (SHP) plays an essential role in the regulation of innate immune and inflammatory responses. The aim of the present study was to identify whether SHP levels are associated with cancer immunology and treatment outcomes in rectal cancer. SHP expression was analyzed via gene set enrichment analysis and the OncoLnc database. In addition, immunohistochemistry and reverse transcription-quantitative PCR analyses were performed on the tissues of patients with locally advanced rectal cancer, and the associations of SHP expression with the clinicopathological and hematological features or treatment response to preoperative radiochemotherapy (pRCT) were analyzed retrospectively. Furthermore, the present study investigated whether SHP expression correlated with immune infiltration levels and immune checkpoint molecules in rectal cancer. The results revealed that low SHP mRNA expression was significantly associated with an inflammatory response and poor prognosis. The nuclear expression of SHP was associated with clinical N stage, neutrophil count, lymphocyte count, neutrophil-lymphocyte ratio and complete pathologic response following pRCT. The low nuclear expression of SHP was associated with poor overall and distant metastasis-free survival (DMFS). In multivariate analysis, the low nuclear expression of SHP was identified as a significant independent prognostic factor for DMFS and a marginally significant prognostic factor for overall survival in rectal cancer. Furthermore, patients with low SHP expression exhibited higher neutrophil and CD[8.sup.+] T cell infiltration levels and higher PD-L1 expression in rectal adenocarcinoma. These results indicate that SHP may act as an anti-inflammatory mediator via the regulation of systemic and local immune responses in rectal cancer. Moreover, SHP might be useful a potential marker or therapeutic target in rectal cancer. Key words: rectal cancer, small heterodimer partner, cancer-related inflammation, radiochemotherapy, prognosis
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2021.12969